X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
humans (14) 14
adult (13) 13
female (13) 13
male (13) 13
human immunodeficiency virus--hiv (12) 12
hiv infections - drug therapy (10) 10
middle aged (10) 10
double-blind method (8) 8
drug therapy (8) 8
anti-hiv agents - therapeutic use (7) 7
antiretroviral drugs (7) 7
clinical trials (7) 7
hiv (7) 7
infection (7) 7
infectious diseases (7) 7
viral load (7) 7
abridged index medicus (6) 6
cd4 lymphocyte count (6) 6
emtricitabine (6) 6
hiv infections - virology (6) 6
infections (6) 6
infectious disease (6) 6
internal medicine (6) 6
tenofovir (6) 6
treatment outcome (6) 6
antiretroviral therapy (5) 5
drug administration schedule (5) 5
hiv infection (5) 5
hiv-1 (5) 5
medicine, general & internal (5) 5
research (5) 5
safety (5) 5
adenine - analogs & derivatives (4) 4
anti-hiv agents - adverse effects (4) 4
antiviral agents (4) 4
cd4 antigen (4) 4
combination therapy (4) 4
hiv patients (4) 4
mutation (4) 4
raltegravir potassium (4) 4
ritonavir - therapeutic use (4) 4
acquired immune deficiency syndrome--aids (3) 3
adenine - therapeutic use (3) 3
aged (3) 3
analysis (3) 3
deoxycytidine - analogs & derivatives (3) 3
diarrhea (3) 3
drug dosages (3) 3
drug therapy, combination (3) 3
drugs (3) 3
health aspects (3) 3
hiv infections - immunology (3) 3
hiv protease inhibitors - therapeutic use (3) 3
hiv-1 - drug effects (3) 3
hospitals (3) 3
lamivudine (3) 3
mexico (3) 3
nucleosides (3) 3
patients (3) 3
pyrrolidinones - administration & dosage (3) 3
pyrrolidinones - adverse effects (3) 3
pyrrolidinones - therapeutic use (3) 3
rna, viral - blood (3) 3
studies (3) 3
tablets (3) 3
usage (3) 3
viral load - drug effects (3) 3
young adult (3) 3
abacavir (2) 2
abacavir-lamivudine (2) 2
adenine - administration & dosage (2) 2
adults (2) 2
anti-hiv agents (2) 2
anti-retroviral agents - adverse effects (2) 2
anti-retroviral agents - therapeutic use (2) 2
atazanavir sulfate (2) 2
benzoxazines - administration & dosage (2) 2
benzoxazines - adverse effects (2) 2
bone-mineral density (2) 2
cholesterol (2) 2
clinical medicine (2) 2
cobicistat (2) 2
cross infection (2) 2
daily lopinavir/ritonavir (2) 2
deoxycytidine - therapeutic use (2) 2
disease (2) 2
dosage and administration (2) 2
double-blind (2) 2
drug combinations (2) 2
drug therapy, combination - adverse effects (2) 2
efavirenz (2) 2
exposure (2) 2
heterocyclic compounds, 3-ring - adverse effects (2) 2
highly active antiretroviral therapy (2) 2
hiv integrase inhibitors - administration & dosage (2) 2
hiv integrase inhibitors - therapeutic use (2) 2
hiv-1 - genetics (2) 2
hiv-1-infected patients (2) 2
human immunodeficiency virus (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 700 - 708
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 1, pp. 43 - 52
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 12, pp. 907 - 915
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9639, pp. 646 - 655
Journal Article